Immunotherapy, especially immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors), has been shown to have important clinical value in the perioperative treatment of patients with early-stage NSCLC (33, 34). This evidence concerns the gene CD274 and non-small cell lung carcinoma.